Issue on Jun-20 : Biotech Supply Chain Vulnerability The major issue highlighted is the vulnerability of the global biotech supply chain, especially due to heavy reliance on foreign raw materials and active pharmaceutical ingredients from countries like China and India. This dependency poses risks to national drug manufacturing and calls for diversification, enhanced government-industry collaboration,…
Issue on Jun-20 : FDA Inspection Observations and Regulatory Approvals 여러 바이오테크 및 제약 회사들이 미국 FDA의 검사에서 관찰 사항을 받거나, 신약 및 치료제에 대한 승인을 받는 등 규제 관련 이슈가 주요 뉴스로 부각되고 있습니다. 이는 기업들의 제품 품질 관리와 신약 개발에 직접적인 영향을 미치며, 투자자 및 시장에 큰 파장을 일으키고 있습니다. Natco Pharma는 하이데라바드에…
Issue on Jun-19 : Pharmaceutical Legal and Regulatory Challenges The most impactful issue highlighted is the ongoing legal settlements and regulatory scrutiny faced by pharmaceutical companies such as Purdue Pharma’s $7 billion opioid settlement, FDA inspections and procedural observations for companies like Glenmark Pharmaceuticals, and investigations into companies like Rocket Pharmaceuticals. These challenges significantly affect…
Issue on Jun-18 : Biotech Mergers and Acquisitions The most significant issue highlighted is the surge in mergers and acquisitions within the biotech sector, exemplified by Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics. This trend reflects the strategic importance of gene-editing and experimental medicine technologies for long-term growth and innovation in the pharmaceutical industry….
Issue on Jun-17 : Purdue Pharma Opioid Settlement The most impactful issue is the $7.4 billion settlement by Purdue Pharma and the Sackler family with all 50 U.S. states and territories to resolve lawsuits related to the opioid epidemic. This settlement is a landmark event in the pharmaceutical industry and public health, addressing the opioid…
